Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 134Carcinoma, Non-Small-Cell Lung 133Prostatic Neoplasms 87Lung Neoplasms 43Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Neoplasm Metastasis 29Stomach Neoplasms 26Head and Neck Neoplasms 24Esophageal Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 17Pancreatic Neoplasms 17Ovarian Neoplasms 16Urinary Bladder Neoplasms 13Sarcoma 12Adenocarcinoma of Lung 9Triple Negative Breast Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Transitional Cell 8Carcinoma, Ovarian Epithelial 8Adenocarcinoma Of Esophagus 7Recurrence 6Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma 5Breast Neoplasms, Male 5Adenocarcinoma, Bronchiolo-Alveolar 5Laryngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumors 4

Interventions

enzalutamide 3cabazitaxel 3Prednisone 3Docetaxel 2Abiraterone Acetate 2rucaparib 1Zuclomiphene 1XRP6258 1Standard of Care 1LY3023414 1Injections 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Prostate Cancer Metastatic × Docetaxel × Clear all
NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

Phase 2 Completed
135 enrolled 29 charts
Genitourinary

Prostate Cancer Metastatic

NCT01718353 2017-11-20

TAXYNERGY

Sanofi

Phase 2 Completed
63 enrolled 13 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡